ImmunoGen, Inc., a company involved in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, entered into a multi-target license and option agreement to research first-in-class ADCs with ImmunoBiochem Corp., a biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biologics. The collaboration will combine ImmunoGen’s linker-payload technology with ImmunoBiochem’s antibodies directed against specific targets. ImmunoBi...